Henrik Kjölhede1, Göran Ahlgren2, Helen Almquist3, Fredrik Liedberg2, Kerstin Lyttkens3, Thomas Ohlsson4, Ola Bratt5. 1. Section of Urology, Department of Surgery, Växjö Hospital, Lund University, 351 85, Växjö, Sweden. henrik.kjolhede@med.lu.se. 2. Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden. 3. Center for Medical Imaging and Physiology, Skåne University Hospital, Lund University, Lund, Sweden. 4. Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden. 5. Department of Urology, Helsingborg Hospital, Lund University, Helsingborg, Sweden.
Abstract
PURPOSE: Salvage radiotherapy (SRT) for biochemical recurrence (BCR) following radical prostatectomy (RP) should if possible be added at a prostate-specific antigen (PSA) level of <1-2 ng/mL. The value of positron emission tomography combined with computed tomography (PET/CT) at such low PSA values is not defined. The purpose was to determine what proportion of a well-defined cohort of hormone-naïve patients who were candidates for early salvage radiotherapy had (18)F-choline PET/CT findings suggesting metastases. MATERIALS AND METHODS: Patients with untreated BCR following RP, PSA <2 ng/mL, and Gleason score ≥7 or PSA doubling time ≤6 months underwent (18)F-choline PET/CT. Focal choline uptake in lymph nodes or skeletal sites was recorded. RESULTS: PET/CT indicated metastases in 16 (28 %) of 58 patients. In five (9 %) patients, the scans suggested bone metastases, and in 11 (19 %) patients, the scans suggested regional lymph node metastases only. For patients with PSA levels <1.0 ng/mL, the PET/CT scans indicated metastatic recurrence in 25 %. CONCLUSIONS: (18)F-choline PET/CT may be valuable for selecting patients with BCR following RP for SRT or experimental treatment of oligometastases, even at low PSA values.
PURPOSE: Salvage radiotherapy (SRT) for biochemical recurrence (BCR) following radical prostatectomy (RP) should if possible be added at a prostate-specific antigen (PSA) level of <1-2 ng/mL. The value of positron emission tomography combined with computed tomography (PET/CT) at such low PSA values is not defined. The purpose was to determine what proportion of a well-defined cohort of hormone-naïve patients who were candidates for early salvage radiotherapy had (18)F-choline PET/CT findings suggesting metastases. MATERIALS AND METHODS:Patients with untreated BCR following RP, PSA <2 ng/mL, and Gleason score ≥7 or PSA doubling time ≤6 months underwent (18)F-choline PET/CT. Focal choline uptake in lymph nodes or skeletal sites was recorded. RESULTS: PET/CT indicated metastases in 16 (28 %) of 58 patients. In five (9 %) patients, the scans suggested bone metastases, and in 11 (19 %) patients, the scans suggested regional lymph node metastases only. For patients with PSA levels <1.0 ng/mL, the PET/CT scans indicated metastatic recurrence in 25 %. CONCLUSIONS: (18)F-choline PET/CT may be valuable for selecting patients with BCR following RP for SRT or experimental treatment of oligometastases, even at low PSA values.
Authors: Ulrike Schick; Sandra Jorcano; Philippe Nouet; Michel Rouzaud; Hansjoerg Vees; Thomas Zilli; Osman Ratib; Damien C Weber; Raymond Miralbell Journal: Acta Oncol Date: 2013-04-02 Impact factor: 4.089
Authors: Ludwig Rinnab; Felix M Mottaghy; Norbert M Blumstein; Sven N Reske; Richard E Hautmann; Kathrin Hohl; Peter Möller; Thomas Wiegel; Rainer Kuefer; Juergen E Gschwend Journal: BJU Int Date: 2007-10 Impact factor: 5.588
Authors: B J Krause; M Souvatzoglou; M Tuncel; K Herrmann; A K Buck; C Praus; T Schuster; H Geinitz; U Treiber; M Schwaiger Journal: Eur J Nucl Med Mol Imaging Date: 2007-09-22 Impact factor: 9.236
Authors: Anna Bill-Axelson; Lars Holmberg; Hans Garmo; Jennifer R Rider; Kimmo Taari; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Anders Spångberg; Ove Andrén; Juni Palmgren; Gunnar Steineck; Hans-Olov Adami; Jan-Erik Johansson Journal: N Engl J Med Date: 2014-03-06 Impact factor: 91.245
Authors: Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack Journal: J Clin Oncol Date: 2007-05-20 Impact factor: 44.544
Authors: David Pfister; Michel Bolla; Alberto Briganti; Peter Carroll; Cesare Cozzarini; Steven Joniau; Hein van Poppel; Mack Roach; Andrew Stephenson; Thomas Wiegel; Michael J Zelefsky Journal: Eur Urol Date: 2013-08-15 Impact factor: 20.096
Authors: Nicola L Robertson; Evis Sala; Matthias Benz; Jonathan Landa; Peter Scardino; Howard I Scher; Hedvig Hricak; Hebert A Vargas Journal: J Urol Date: 2017-02-16 Impact factor: 7.450
Authors: Lars J Petersen; Julie B Nielsen; Katja Dettmann; Rune V Fisker; Uwe Haberkorn; Louise Stenholt; Helle D Zacho Journal: Mol Clin Oncol Date: 2017-05-31